Free Trial

LENSAR (LNSR) Competitors

LENSAR logo
$12.95 +0.02 (+0.15%)
As of 10:54 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

LNSR vs. BBNX, EMBC, SMLR, CBLL, KIDS, AVNS, BVS, AXGN, BFLY, and DCTH

Should you be buying LENSAR stock or one of its competitors? The main competitors of LENSAR include Beta Bionics (BBNX), Embecta (EMBC), Semler Scientific (SMLR), CeriBell (CBLL), OrthoPediatrics (KIDS), AVANOS MEDICAL (AVNS), Bioventus (BVS), AxoGen (AXGN), Butterfly Network (BFLY), and Delcath Systems (DCTH). These companies are all part of the "medical equipment" industry.

LENSAR vs. Its Competitors

LENSAR (NASDAQ:LNSR) and Beta Bionics (NASDAQ:BBNX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

LENSAR presently has a consensus target price of $15.00, indicating a potential upside of 15.83%. Beta Bionics has a consensus target price of $23.44, indicating a potential upside of 62.92%. Given Beta Bionics' stronger consensus rating and higher possible upside, analysts clearly believe Beta Bionics is more favorable than LENSAR.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LENSAR
0 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Beta Bionics
0 Sell rating(s)
4 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.75

In the previous week, Beta Bionics had 5 more articles in the media than LENSAR. MarketBeat recorded 7 mentions for Beta Bionics and 2 mentions for LENSAR. LENSAR's average media sentiment score of 1.87 beat Beta Bionics' score of 0.86 indicating that LENSAR is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
LENSAR
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Beta Bionics
3 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

40.2% of LENSAR shares are owned by institutional investors. 38.5% of LENSAR shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

LENSAR has higher earnings, but lower revenue than Beta Bionics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LENSAR$53.49M2.85-$31.40M-$4.85-2.67
Beta Bionics$65.12M9.58-$54.76MN/AN/A

Beta Bionics has a net margin of 0.00% compared to LENSAR's net margin of -99.17%. Beta Bionics' return on equity of 0.00% beat LENSAR's return on equity.

Company Net Margins Return on Equity Return on Assets
LENSAR-99.17% -737.30% -81.69%
Beta Bionics N/A N/A N/A

Summary

Beta Bionics beats LENSAR on 10 of the 14 factors compared between the two stocks.

Get LENSAR News Delivered to You Automatically

Sign up to receive the latest news and ratings for LNSR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LNSR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LNSR vs. The Competition

MetricLENSARMED INSTRUMENTS IndustryMedical SectorNASDAQ Exchange
Market Cap$152.68M$6.94B$5.71B$9.50B
Dividend YieldN/A1.28%4.60%3.99%
P/E Ratio-2.6725.4927.8819.97
Price / Sales2.8550.80452.35101.58
Price / CashN/A20.6736.5558.97
Price / Book30.834.718.635.89
Net Income-$31.40M$176.14M$3.24B$258.50M
7 Day Performance-1.15%2.63%3.90%2.07%
1 Month Performance3.60%3.11%10.47%12.39%
1 Year Performance141.15%8.61%34.29%19.25%

LENSAR Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LNSR
LENSAR
1.3651 of 5 stars
$12.95
+0.2%
$15.00
+15.8%
+149.1%$152.68M$53.49M-2.67110Positive News
BBNX
Beta Bionics
N/A$14.30
+5.2%
$23.44
+63.9%
N/A$589.21M$65.12M0.00294News Coverage
Lockup Expiration
EMBC
Embecta
4.6843 of 5 stars
$10.29
+5.2%
$19.00
+84.6%
-30.4%$571.57M$1.12B11.432,100
SMLR
Semler Scientific
2.6432 of 5 stars
$39.67
-3.8%
$89.00
+124.4%
+18.1%$568.63M$56.29M-15.20120
CBLL
CeriBell
2.3806 of 5 stars
$15.21
-2.4%
$32.14
+111.3%
N/A$563.11M$65.44M0.00N/A
KIDS
OrthoPediatrics
4.194 of 5 stars
$21.88
-0.6%
$35.83
+63.8%
-32.8%$534.56M$212.45M-12.50200
AVNS
AVANOS MEDICAL
2.9456 of 5 stars
$11.40
+1.6%
N/A-47.3%$518.86M$687.80M-1.362,227News Coverage
Upcoming Earnings
BVS
Bioventus
3.3652 of 5 stars
$6.30
+0.6%
$13.75
+118.3%
-14.2%$517.51M$567.70M-10.331,200
AXGN
AxoGen
2.2863 of 5 stars
$11.61
+2.9%
$24.50
+111.0%
+42.5%$513.74M$194.52M-77.39450
BFLY
Butterfly Network
2.5547 of 5 stars
$1.89
+0.8%
$3.50
+85.7%
+93.1%$462.43M$82.06M-6.50460News Coverage
Upcoming Earnings
DCTH
Delcath Systems
2.6412 of 5 stars
$11.32
+0.6%
$24.00
+112.0%
+29.0%$391.80M$37.21M-22.6460

Related Companies and Tools


This page (NASDAQ:LNSR) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners